Tekla Life Sciences Investors (NYSE:HQL – Get Rating) saw a significant decrease in short interest in the month of December. As of December 15th, there was short interest totalling 14,200 shares, a decrease of 10.7% from the November 30th total of 15,900 shares. Based on an average daily trading volume, of 96,600 shares, the days-to-cover ratio is presently 0.1 days.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in the business. Kingsview Wealth Management LLC boosted its holdings in Tekla Life Sciences Investors by 2.8% during the third quarter. Kingsview Wealth Management LLC now owns 37,158 shares of the company’s stock worth $508,000 after purchasing an additional 1,008 shares during the last quarter. Cohen & Steers Inc. boosted its holdings in Tekla Life Sciences Investors by 49.8% during the third quarter. Cohen & Steers Inc. now owns 83,125 shares of the company’s stock worth $1,135,000 after purchasing an additional 27,636 shares during the last quarter. 1607 Capital Partners LLC acquired a new position in Tekla Life Sciences Investors during the third quarter worth $1,160,000. Nations Financial Group Inc. IA ADV lifted its stake in Tekla Life Sciences Investors by 18.8% in the third quarter. Nations Financial Group Inc. IA ADV now owns 13,900 shares of the company’s stock valued at $190,000 after acquiring an additional 2,200 shares during the last quarter. Finally, Cornerstone Advisors LLC lifted its stake in Tekla Life Sciences Investors by 1,222.1% in the third quarter. Cornerstone Advisors LLC now owns 178,490 shares of the company’s stock valued at $2,438,000 after acquiring an additional 164,990 shares during the last quarter. Institutional investors and hedge funds own 15.95% of the company’s stock.
Tekla Life Sciences Investors Stock Up 0.7 %
Shares of Tekla Life Sciences Investors stock traded up $0.10 on Tuesday, hitting $14.31. The company had a trading volume of 11,674 shares, compared to its average volume of 138,548. Tekla Life Sciences Investors has a twelve month low of $13.03 and a twelve month high of $19.43. The stock has a 50-day moving average of $14.68 and a 200-day moving average of $14.66.
Tekla Life Sciences Investors Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Friday, December 30th. Investors of record on Friday, November 25th were issued a dividend of $0.31 per share. This represents a $1.24 annualized dividend and a yield of 8.67%. The ex-dividend date of this dividend was Wednesday, November 23rd.
Tekla Life Sciences Investors Company Profile
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to email@example.com.
Before you consider Tekla Life Sciences Investors, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Tekla Life Sciences Investors wasn’t on the list.
While Tekla Life Sciences Investors currently has a “hold” rating among analysts, top-rated analysts believe these five stocks are better buys.